Ban on pay-for-delay deals might get dropped from health bill

03/17/2010 | Wall Street Journal, The

A complex process that Congress will use to vote on the health reform bill might lead to the exclusion of a proposal to ban pay-for-delay deals between brand-name and generic-drug firms. Sen. Herb Kohl, D-Wis., intends to push the provision later if it gets dropped from the overhaul legislation, a spokeswoman said.

View Full Article in:

Wall Street Journal, The